5 October 2016
New MM treatment gains funding
SkylineDx has received Horizon 2020 funding to develop a gene-expression profiling technology intended to predict treatment strategies for patients with multiple myeloma (MM).
The announcement comes as SkylineDx prepares for its sponsorship and support at the European School of Haematology’s 3rd International Conference on Multiple Myeloma in Milan, Italy, between 7-9 October 2016.
SkylineDx has also developed the MMprofiler with SKY92, a gene-expression-based risk identification signature that determines the level of risk for patients with MM by classifying them into a “high” or “standard” risk group.
Dharminder Chahal, CEO of SkylineDx, said: “SkylineDx appreciates all of the support of our partners and is looking forward to expanding the portfolio to help physicians personalise treatment options for those who receive a diagnosis of MM.
“Helping healthcare professionals make precision medicine treatment decisions for their patients has always been at the forefront of SkylineDx’s mission and we believe that this test will give patients the chance to improve their survival and quality of life.”
Andrzej Jakubowiak, professor of medicine and director of the University of Chicago’s myeloma programme, added: “We need to incorporate tools like the MMprofiler in order to best identify those patients who may benefit from a more aggressive treatment regime versus those who may benefit from a less aggressive treatment.
“Tools like the MMprofiler are absolutely important to help us not to lose sight of what’s best for our patients.”
The consortium of European partners includes Erasmus MC; Myeloma Patients Europe; the University of Turin, Italy, and the Institute for Medical Technology Assessment, the Netherlands.